Skip to main
RVTY
RVTY logo

Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity Inc (RVTY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Revvity, formed from the rebranding of PerkinElmer, has exhibited a materially improved growth rate and margin profile, bolstered by strategic acquisitions, including BioLegend and EUROIMMUN, which enhance its life sciences and immunodiagnostics franchises. The company's ongoing shift from TST to IGRA is expected to contribute to annual market growth, alongside the expansion of its high-growth software segment, Signals, which accounts for approximately 10% of sales and offers recurring revenue potential. Furthermore, operational efficiencies and strong demand in its key markets—particularly in the US, which represents around 40% of revenue—position Revvity favorably for continued profitability and market share gains in the biopharma and diagnostics sectors.

Bears say

Revvity's stock faces a negative outlook primarily due to declining revenues, particularly in China, where Immunodiagnostics experienced a significant drop in sales, contributing to an overall revenue decline. The potential for slower customer demand is heightened by adverse economic conditions and funding cuts, which may further hamper market share and growth prospects. Additionally, macroeconomic challenges, such as product shortages and inflationary pressures across the supply chain, could further impede Revvity's operational efficiency and product delivery.

Revvity Inc (RVTY) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Revvity Inc (RVTY) Forecast

Analysts have given Revvity Inc (RVTY) a Buy based on their latest research and market trends.

According to 11 analysts, Revvity Inc (RVTY) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $113.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $113.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Revvity Inc (RVTY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.